Lilly reports positive late-phase results for new diabetes drug

A new drug from Eli Lilly and Co. showed "encouraging" results in two late-phase studies with type 2 diabetes patients, according to Enrique Conterno, president of Lilly Diabetes. The once-weekly injectable drug dulaglutide met efficacy goals of reducing hemoglobin A1c levels, a measure of blood sugar.

View Full Article in:

Indianapolis Star (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN